glp-1 and alzheimer's disease drugs failed to slow in two big clinical trials 🧠✨ New research is uncovering

& Wells, C

General health | urgent & non-urgent care: PlushCare Telehealth | Skip to review General health | hair loss: PlushCare Hair Loss Treatments | Skip to review General health | menopause: PlushCare for HRT | Skip to review Sexual health | treatments: PlushCare for STD Treatment Online | Skip to review Sexual health | men's health: PlushCare ED Medications | Skip to review Weight loss | treatments and plans: PlushCare Medical Weight Loss Programs | Skip to review Mental health | online therapy: PlushCare Mental Health | Skip to review PlushCare is a telehealth platform that offers a range of healthcare services, including mental health, prescription refills, and weight loss programs

Over the past year, the clinical and regulatory landscape of GLP-1s has evolved with new indications and approvals expanding their use

For example, alterations in Wnt signalling, alterations in neuronal translation and defects in synaptogenesis or synaptic function during brain development can all affect the formation and activity of neural circuits

These SCFAs stimulate GLP-1 secretion via the gut microbiome and help regulate inflammation, appetite, and blood sugar

3) Diabetes In 2 studies on almost 3,000 people, high TMAO levels were associated with increased rates of type 2 diabetes [17, 18]